Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Receivables - Net: 2023-2024

Historic Receivables - Net for Tarsus Pharmaceuticals (TARS) over the last 2 years, with Dec 2024 value amounting to $46.8 million.

  • Tarsus Pharmaceuticals' Receivables - Net rose 149.05% to $72.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $72.6 million, marking a year-over-year increase of 149.05%. This contributed to the annual value of $46.8 million for FY2024, which is 181.33% up from last year.
  • As of FY2024, Tarsus Pharmaceuticals' Receivables - Net stood at $46.8 million, which was up 181.33% from $16.6 million recorded in FY2023.
  • In the past 5 years, Tarsus Pharmaceuticals' Receivables - Net ranged from a high of $46.8 million in FY2024 and a low of $16.6 million during FY2023.
  • Its 2-year average for Receivables - Net is $31.7 million, with a median of $31.7 million in 2023.
  • Data for Tarsus Pharmaceuticals' Receivables - Net shows a peak YoY soared of 181.33% (in 2024) over the last 5 years.
  • Tarsus Pharmaceuticals' Receivables - Net (Yearly) stood at $16.6 million in 2023, then spiked by 181.33% to $46.8 million in 2024.